Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients

The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

NCT03963375 ·Status: COMPLETED ·Phase: PHASE4

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 ·Status: COMPLETED ·Phase: PHASE2

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT00213135 ·Status: COMPLETED ·Phase: PHASE3

Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies

NCT06894940 ·Status: COMPLETED ·Phase: PHASE2

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826 ·Status: COMPLETED ·Phase: PHASE2

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

NCT07189325 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331 ·Status: COMPLETED ·Phase: PHASE2

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome

NCT00666224 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis

NCT01199640 ·Status: COMPLETED ·Phase: PHASE2

Safety of RG2077 in Patients With Multiple Sclerosis

NCT00076934 ·Status: COMPLETED ·Phase: PHASE1

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

NCT01701856 ·Status: TERMINATED ·Phase: PHASE4

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

NCT00134563 ·Status: COMPLETED ·Phase: PHASE3

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248 ·Status: RECRUITING ·Phase: PHASE2

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161 ·Status: COMPLETED ·Phase: PHASE2

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

NCT01435993 ·Status: TERMINATED ·Phase: PHASE1

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

NCT01569451 ·Status: COMPLETED ·Phase: PHASE2

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

NCT03933202 ·Status: COMPLETED

Cladribine Tablets as an Exit Therapy Strategy

NCT06887426 ·Status: NOT_YET_RECRUITING

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

NCT04934800 ·Status: COMPLETED

Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis

NCT05078177 ·Status: UNKNOWN ·Phase: PHASE1

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

NCT02398461 ·Status: COMPLETED ·Phase: PHASE1

Effect of Cladribine Treatment on Microglial Activation in the CNS

NCT04239820 ·Status: ACTIVE_NOT_RECRUITING

Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)

NCT05828901 ·Status: TERMINATED